Tarsus Pharmaceuticals, Inc.
TARSNASDAQHealthcareBiotechnology
Latest quote
$72.70
+$1.21 · +1.69%
TARS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
82
Deep Value
Momentum
40
Weakening
Sentiment
52
Mixed
Risk resilience
49
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Bobak R. Azamian
- Listed since
- Oct 16, 2020
- Employees
- 370
Market position
- Volume
- 636.34K
- 0.72× average
- Average volume
- 885.4K
- Average daily volume
- Market cap
- 3.13B USD
- Beta
- 0.51
- Market reference 1
TARS peers
ETFs holding TARS
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI76.86M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM76.72M0.09%81.62B USD0.19%$299.96+0.77%
iShares Russell 2000 Growth ETFIWO27.82M0.19%15.16B USD0.24%$387.37+1.24%
Vanguard Extended Market ETFVXF26.93M0.03%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB21.52M0.20%10.75B USD0.44%$213.56+1.29%
Invesco Pharmaceuticals ETFPJP15.23M2.88%535.56M USD0.57%$130.06+0.91%
Vanguard Russell 2000 ETFVTWO13.87M0.08%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA13.47M0.06%23.1B USD0.03%$34.83+0.52%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 76.86M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 76.72M
- Weight
- 0.09%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
iShares Russell 2000 Growth ETFIWO- Market value
- 27.82M
- Weight
- 0.19%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard Extended Market ETFVXF- Market value
- 26.93M
- Weight
- 0.03%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 21.52M
- Weight
- 0.20%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Invesco Pharmaceuticals ETFPJP- Market value
- 15.23M
- Weight
- 2.88%
- AUM
- 535.56M USD
- Expense ratio
- 0.57%
- Price / 1D
- $130.06+0.91%
Vanguard Russell 2000 ETFVTWO- Market value
- 13.87M
- Weight
- 0.08%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 13.47M
- Weight
- 0.06%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research TARSresearch.disclaimer